We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

An Open-labeled Trial of Ramipril in Patients With Migraine

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01402479
Recruitment Status : Completed
First Posted : July 26, 2011
Last Update Posted : August 8, 2011
Information provided by:

July 24, 2011
July 26, 2011
August 8, 2011
October 2004
July 2005   (Final data collection date for primary outcome measure)
headache frequency [ Time Frame: 12 week ]
headache days
Same as current
Complete list of historical versions of study NCT01402479 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
An Open-labeled Trial of Ramipril in Patients With Migraine
An Open-labeled Trial of Ramipril in Patients With Migraine
Physiology of migraine involving renin-angiotensin systems (RAS) has been implicated. Ramipril is a broadly-used angiotensin-converting enzyme inhibitor. The investigators attempt to test the efficacy of ramipril on the prophylaxis of migraine attacks.
Not Provided
Phase 2
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Migraine With Hypertension
Drug: Ramipril
ramipril 2.5mg twice a day
Active Comparator: ramipril
open label single arm trial
Intervention: Drug: Ramipril
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
July 2005
July 2005   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients with chronic migraine are included in this study. Migraineurs should be aged 20 to 70 years old with the ability to read and understand the self-report scales, including the headache diary, used in this study.

Exclusion Criteria:

  1. Medication overuse headache are excluded in this study.
  2. Treatment with other ACEI or medication that may affect ARS
  3. Treatment with migraine prophylactic medications or anti-hypertensive agents including β adrenergic receptor or calcium channel blockers
  4. Past history of hepatic or renal dysfunction; an abnormal electrocardiography; a psychiatric disorder; a history of substance abuse; pregnancy or lactation; use of anti-psychotics, antidepressants, or anti-anxiety drugs.
Sexes Eligible for Study: All
20 Years to 70 Years   (Adult, Senior)
Not Provided
Contact information is only displayed when the study is recruiting subjects
Korea, Republic of
Not Provided
Not Provided
Manho Kim, MD, PhD, Department of Neurology, Seoul National University Hospital
Seoul National University Hospital
Not Provided
Not Provided
Seoul National University Hospital
July 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP